Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for induced pluripotent stem cell-derived macrophage cell therapies
London, UK and Toronto, Canada, 7 November, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, CCRM, one of the leading companies developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and OmniaBio Inc., CCRM’s subsidiary, today announced a research collaboration to develop and scale up a manufacturing platform for Resolution’s off-the-shelf iPSC-derived macrophage cell therapies.
“An off-the-shelf product offering will reduce the complexity of the supply chain of our macrophage cell therapeutics. Allogeneic cell therapy will facilitate access to a greater number of treatment centres with potential to provide benefit to a larger group of patients with advanced liver disease. We are excited to partner with CCRM, a company with state-of-the-art facilities, deep expertise in manufacturing of iPSC-derived cell therapy and a track record of translating regenerative medicine-based technologies towards clinical development,” said Edward Hodgkin, CEO of Resolution. “The collaboration with CCRM and OmniaBio will enable us to build a scalable, GMP-compatible manufacturing platform for our off-the-shelf iPSC-derived macrophage cell therapies.”
“Resolution is a leader in the development of macrophage-based cell therapies,” said Michael May, President and CEO of CCRM. “We are delighted to be working with their team and look forward to leveraging our deep expertise in iPSC differentiation, process development and GMP manufacturing to enable Resolution Therapeutics’ efforts and accelerate the delivery of breakthrough medicines to patients in need.”
“The project with Resolution is being executed by OmniaBio, leveraging the technical skills within the teams at CCRM and OmniaBio,” explains Mitchel Sivilotti, CEO of OmniaBio Inc. “The launch of OmniaBio creates end-to-end support for companies like Resolution who need to move from process development to clinical-stage manufacturing and eventually commercial-scale manufacturing. OmniaBio has the expertise, infrastructure and a strong focus on cell and gene therapies to deliver impact on this project and eventually to patients.”
– Ends –
|+44 (0)7818 430877|
|CCRM and OmniaBio
|+1 (647) 309 1830|
Notes for Editors:
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com
CCRM is a global, public-private partnership headquartered in Canada. It receives funding from the Government of Canada, the Province of Ontario and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for manufacturing cell and gene therapies. CCRM is the commercialization partner of the University of Toronto’s Medicine by Design. CCRM is hosted by the University of Toronto. www.ccrm.ca
OmniaBio Inc. is a CDMO with pre-clinical to commercial-scale manufacturing capability for cell and gene therapies, and a subsidiary of CCRM. Benefitting from CCRM’s existing expertise and established business practices, OmniaBio provides a continuum of advanced process and analytical development, and manufacturing capabilities by enabling focused support for clients from early clinical phase to commercial supply needs. OmniaBio is built upon leadership in iPSCs, LVVs and immunotherapy. To be located at McMaster Innovation Park, less than one hour from the U.S. border, OmniaBio’s new commercial manufacturing site will anchor a biomanufacturing centre of excellence and will open with late clinical phase and commercial capacity in 2024 in a site totalling approximately 100,000 square feet. OmniaBio is supported by the Government of Ontario, via the Invest Ontario Fund. Visit us at omniabio.com.